Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141917

Published: 2020

Journal Articles

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

Christina Poh, MD, Ebaa Alobeidi, MD, Joseph Tuscano, MD, Aaron S Rosenberg, MD, Rasmus T Hoeg, MD, Brian A Jonas, MD PhD

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-136333

Published: 2020

Journal Articles

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Michael Low Cardenas, MD, Mehrdad Abedi, MD, Christina Romo, Carol M. Richman, MD, Megan Daly, MD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 3334.

https://doi.org/10.1182/blood-2019-130870

Published: 2019

Journal Articles

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

Samantha C Fisch, BS, Brian A Jonas, MD PhD, Joseph Tuscano, MD, Aaron Seth Rosenberg, MD, Rasmus T Hoeg, MD, Mehrdad Abedi, MD

Blood (2019) 134 (Supplement_1): 3884.

https://doi.org/10.1182/blood-2019-121991

Published: 2019

Journal Articles

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Swetha Kambhampati, MD, Bita Fakhri, MDMPH, Weiyun Ai, MD PhD, Lawrence D Kaplan, MD, Joseph Tuscano, MD, Matthew J. Wieduwilt, MD PhD, Akshay Sudhindra, MD, Jimmy Hwang, PhD, Jesika Reiner, MPH, Michelle Martinelli, Charlie Aoun, BS, Teresa Ta, Diem Le, Michelle Padilla, Erika Crawford, Charalambos Andreadis, MD

Blood (2019) 134 (Supplement_1): 2828.

https://doi.org/10.1182/blood-2019-123279

Published: 2019

Journal Articles

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Christina Poh, MD, Paul Frankel, PhD, Christopher Ruel, Mehrdad Abedi, MD, Emily Schwab, BS, Caitlin L. Costello, MD, Jasmine Zain, MD, Lihua E Budde, MD PhD, Basem M. William, MRCP,MD, Francine M. Foss, MD, Brian A Jonas, MD PhD, Aaron Seth Rosenberg, MD, Edward Newman, PhD, Joseph Tuscano, MD

Blood (2019) 134 (Supplement_1): 760.

https://doi.org/10.1182/blood-2019-124254

Published: 2019

Journal Articles

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Aaron Seth Rosenberg, MD, Qian Li, MS, Ann M Brunson, MS, Joseph Tuscano, MD, Ted Wun, MD, Theresa H.M. Keegan, PhD MS

Blood (2018) 132 (Supplement 1): 3598.

https://doi.org/10.1182/blood-2018-99-117959

Published: 2018

Journal Articles

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

Aaron Seth Rosenberg, MD, Thierry Facon, MD, Safiya Abouzaid, MPH, PharmD, Shankar Srinivasan, PhD, Weiyuan Chung, Kejal Parikh, BSPharm, MS, Joseph Tuscano, MD

Blood (2017) 130 (Supplement 1): 3113.

https://doi.org/10.1182/blood.V130.Suppl_1.3113.3113

Published: 2017

Journal Articles

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Joseph Tuscano, MD, Susan Groshen, PhD, Denice Tsao-Wei, Emanual Maverakis, MD, Paul R. Kaesberg, MD, Tanya Siddiqi, MD, Leslie Popplewell**, MD, Sikander Ailawadhi, Myo Htut, Robert W. Chen, MD, Mark Kirschbaum, MD, Mark T. Schroeder, MD, Brian A Jonas, MD PhD, Ted Wun, MD FACP, FRCPA, Neil Palmisiano, MD, David F. Claxton, Edward Newman, PhD

Blood (2017) 130 (Supplement 1): 4086.

https://doi.org/10.1182/blood.V130.Suppl_1.4086.4086

Published: 2017

Journal Articles

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Blood (2016) 128 (22): 2992.

https://doi.org/10.1182/blood.V128.22.2992.2992

Published: 2016

Journal Articles

Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM)

Aaron S Rosenberg, MD MS, Ann M Brunson, MS, Joseph Tuscano, MD, Brian A Jonas, MD PhD, Ted Wun, MD, Theresa Keegan, PhD MS

Blood (2016) 128 (22): 846.

https://doi.org/10.1182/blood.V128.22.846.846

Published: 2016

Journal Articles

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Brian Jonas, MDPhD, Joseph Tuscano, MD, Ted Wun, MD

Blood (2015) 126 (23): 1991.

https://doi.org/10.1182/blood.V126.23.1991.1991

Published: 2015

Journal Articles

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Aaron S Rosenberg, MD MS, Ann M Brunson, BS, Theresa HM Keegan, PhD MSc, Joseph Tuscano, MD, Ted Wun, MD, Brian Jonas, MDPhD

Blood (2015) 126 (23): 1305.

https://doi.org/10.1182/blood.V126.23.1305.1305

Published: 2015

Journal Articles

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Barbara Marie Galligan, MD, Denice Tsao-Wei, Susan Groshen, Mark Kirschabum, Robert O'Donnell, Paul R. Kaesberg, MD, Tanya Siddiqui, Leslie Popplewell, Ailawadhi Sikander, Htut Myo, Robert Chen, John F. DiPersio, MD PhD, Neil D. Palmisiano, MD, David F. Claxton, MD, Edward M. Newman, PhD, Joseph Tuscano, MD

Blood (2015) 126 (23): 3977.

https://doi.org/10.1182/blood.V126.23.3977.3977

Published: 2015

Journal Articles

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Tanya Siddiqi, MD, Anna Scuto, PhD, Jan H. Beumer, PharmD, PhD, Joo Y. Song, MD, Paul Frankel, PhD, Chris Ruel, MS, Jacob Cobb, BS, Brian F. Kiesel, BS, Dennis D. Weisenburger, MD, Kevin R. Kelly, MD PhD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, PhD MD, Edward M. Newman, PhD

Blood (2015) 126 (23): 2731.

https://doi.org/10.1182/blood.V126.23.2731.2731

Published: 2015

Journal Articles

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates

Noriko Satake, MD, Connie Duong, BS, Michael Oestergaard, Sakiko Yoshida, MDPhD, Cathy Chen, Jan A. Nolta, PhD, Shuling Guo, PhD, Punit Seth, PhD, Nitin Nitin, PhD, Joseph Tuscano, MD

Blood (2014) 124 (21): 3719.

https://doi.org/10.1182/blood.V124.21.3719.3719

Published: 2014

Journal Articles

A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era

Aaron Rosenberg, MD MS, Ann Brunson, BS, Joseph Tuscano, MD, Richard H. White, MD, Ted Wun, MD

Blood (2014) 124 (21): 2609.

https://doi.org/10.1182/blood.V124.21.2609.2609

Published: 2014

Journal Articles

Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B Cell Acute Lymphoblastic Leukemia

Sakiko Yoshida, MDPhD, Emily Tuscano, Connie Duong, BS, Joseph Tuscano, MD, Noriko Satake, MD

Blood (2014) 124 (21): 971.

https://doi.org/10.1182/blood.V124.21.971.971

Published: 2014

Journal Articles

Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma

Xiao-Dong Li, PhD, Ann Brunson, BS, Robert o'Donnell, Professor, Kelly M Jones, BS, Richard B Pollard, Joseph Tuscano, MD

Blood (2014) 124 (21): 4477.

https://doi.org/10.1182/blood.V124.21.4477.4477

Published: 2014

Journal Articles

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Tanya Siddiqi, MD, Paul Frankel, PhD, Chris Ruel, MS, Robert W Chen, MD, Kevin R. Kelly, MD, Joseph Tuscano, MD, Leslie Popplewell, MD, Stephen J. Forman, MD, Richard Piekarz, MD PhD, Edward Newman, PhD

Blood (2014) 124 (21): 4483.

https://doi.org/10.1182/blood.V124.21.4483.4483

Published: 2014

NARROW

Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study

Complications in Acute Myeloid Leukemia Inductions Prior to Count Recovery: A Feasibility Study for Outpatient Care at an Academic Center

The Addition of Ibritumomab Tiuxetan (IT) to the ATG/TLI Preparative Regimen Is Safe and May Enhance Post-Transplant Response and Outcomes for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Study of Escalating Doses of Carfilzomib with Hyper-CVAD in Patients with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma

A Phase 1b Dose Escalation Trial of Carfilzomib in Combination with Bendamustine and Rituximab in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin's Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis

Changing Incidence of Major Cardiovascular Events in Multiple Myeloma Patients over Time

Morbid Progression Is Common Among Patients with Multiple Myeloma and Is Associated with Shortened Overall Survival: Validation of the Progression-Free Survival Endpoint

a Phase I California Cancer Consortium Study of the Combination of Rituximab and Ipilimumab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma; Efficacy, Safety and Immune Correlative Analysis

Serum Biomarkers Predict Outcomes in Advanced Hodgkin Lymphoma Independent of International Prognostic Score (IPS) and Treatment: Correlative Analysis from a Large North American Cooperative Group Trial

Racial/Ethnic and Socioeconomic Disparities in the Use of Autologous Hematopoietic Stem Cell Transplant (ASCT) Among Californians with Multiple Myeloma (MM)

The Effect of Autologous Stem Cell Transplant (ASCT) on Survival in Californians with Multiple Myeloma (MM) in the Era of Modern Treatment

Secondary Acute Lymphoblastic Leukemia (sALL) Is Associated with a Distinct Group of Primary Cancers and Has Prognostic Impact

Efficacy and Safety of Combined Rituximab and Ipilimumab to Treat Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma

Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies

Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates

A Population Based Study of the Incidence and Effect on Mortality of Venous Thromboembolism in Non-Hodgkins Lymphoma Patients in the Rituximab Era

Efficacy of an Anti-CD22 Antibody-Monomethyl Auristatin E Conjugate in a Preclinical Xenograft Model of Precursor B Cell Acute Lymphoblastic Leukemia

Clinical and Correlative Analysis of a Phase 2 Study of Lenalidomide and Rituximab in Previously Untreated Indolent Non-Hodgkin Lymphoma

Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only